Introduction/Background Worldwide, cervical cancer is the fourth cancer in female patients and the fourth cause of death from cancer in women. The high mortality rate from cervical cancer globally (age standardized rate among women: 13.3/100 000 in 2020).

It well known that nearly 90–95% of cervical cancer is due to HPV infection, HPV types 16,18 are responsible for nearly 50% of high-grade cervical pre-cancers. Cervical cancer can be cured if diagnosed at an early stage and treated.

Methodology Comprehensive cervical cancer control includes primary prevention (vaccination against HPV), secondary prevention (screening and treatment of pre-cancerous lesions), tertiary prevention (diagnosis and treatment of invasive cervical cancer) and palliative care.

Different countries have different cervical screening recommendations, but most of them started to follow the ASCCP 2020 guidelines, which they started to use the HPV test alone every 5 years for everyone with a cervix from age 25 until age 65.

Results Recommendations of colposcopy, treatment, or surveillance will be based on a patient‘s risk of CIN 3+ determined by a combination of current results and past history, Guidance for expedited treatment is expanded, Continued surveillance with HPV testing or cotesting at 3-year intervals for at least 25 years is recommended after treatment and initial post-treatment management of histologic HSIL, CIN 2, CIN 3, or AIS.

Surveillance with cytology alone is acceptable only if testing with HPV or cotesting is not feasible. Cytology is less sensitive than HPV testing for detection of precancer and is therefore recommended more often. Cytology is recommended at 6-month intervals when HPV testing or cotesting is recommended annually and annually when 3-year.

Conclusion Cervical cancer is one of important cancers that we have the chance to decrease its incidence and nearly to eradicate.

So we need to keep up with guidelines and the recommendation what ever it is.

Disclosures No disclosure